PURMX Therapeutics draws Nippon Shokubai into convertible funding round

What's the deal? PURMX Therapeutics said on September 29, 2026, that it has raised a convertible funding round. Chemicals maker Nippon ShokubaiDealroom has a profile for this one. Try Dealroom → joined as a new investor. The company issued convertible preferred stock in the transaction.

Why now? The tie-up brings a large industrial player onto PURMX's cap table. For a therapeutics developer, that can signal both capital and a potential manufacturing or research partner.

The signal: Convertible structures let both sides defer pricing until a later round, a common route for early-stage biotech deals. Nippon Shokubai's entry adds a corporate backer to PURMX's investor base as it advances its pipeline.

Read more: in.marketscreener.com

Image credit: Generated with Gemini